Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol - A randomized study

Yu Hung Lin, Jiann-Loung Hwang, Kok Min Seow, Lee Wen Huang, Bih Chwen Hsieh, Chi Ruey Tzeng

Research output: Contribution to journalArticle

29 Citations (Scopus)


This study evaluates the efficacy of a stimulation protocol with clomiphene citrate (CC)/human menopausal gonadotropin (hMG)/cetrorelix and its effects on oocyte quality and endometrium. One hundred and twenty couples with male-factor infertility who were about to undergo their first intracytoplasmic sperm injection cycles were randomized into two groups. Sixty women were stimulated with the CC/hMG/cetrorelix protocol (cetrorelix group) and 60 received the buserelin long protocol (buserelin group). Fewer oocytes were recovered in the cetrorelix group than in the buserelin group (mean ± standard deviation (SD): 11.1 ± 4.0 vs. 17.3 ± 5.8, p <0.001); however, the percentages of metaphase II, metaphase I and germinal vesicle oocytes were similar between the two groups. Serum estradiol level was significantly lower in the cetrorelix than in the buserelin group (mean ± SD: 2600.58 ± 1189.11 vs. 3293.46 ± 1221.49 pg/ml, p = 0.006), but the endometrial thickness was similar. The implantation rates (19.2% vs. 17.7%) and the pregnancy rates (41.7% vs. 40.0%) were similar between groups. The ampoules (mean ± SD: 18.9 ± 3.0 vs. 38.9 ± 12.2, p <0.001) and injections (mean ± SD: 6.8 ± 1.1 vs. 15.7 ± 3.1, p <0.001) of gonadotropin used were significantly lower in the cetrorelix group than in the buserelin group. No patients in either group developed a premature luteinizing hormone surge. The present study found no statistically significant difference between the two treatment modalities with regard to pregnancy rates.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalGynecological Endocrinology
Issue number6
Publication statusPublished - Jun 1 2006



  • Buserelin
  • Cetrorelix
  • Clomiphene citrate
  • Gonadotropin-releasing hormone antagonist

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology

Cite this